See more : MISC Berhad (3816.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Sangamo Therapeutics, Inc. (SGMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sangamo Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Mapfre, S.A. (MAP.MC) Income Statement Analysis – Financial Results
- The Furukawa Battery Co., Ltd. (6937.T) Income Statement Analysis – Financial Results
- Radico Khaitan Limited (RADICO.NS) Income Statement Analysis – Financial Results
- Jinzi Ham Co.,Ltd. (002515.SZ) Income Statement Analysis – Financial Results
- Essence Information Technology Co., Ltd. (688555.SS) Income Statement Analysis – Financial Results
Sangamo Therapeutics, Inc. (SGMO)
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176.23M | 111.30M | 110.70M | 118.19M | 102.43M | 84.45M | 36.57M | 19.39M | 39.54M | 45.87M | 24.13M | 21.66M | 10.32M | 20.81M | 22.19M | 16.19M | 9.10M | 7.89M | 2.48M | 1.32M | 2.58M | 4.34M | 4.89M | 3.43M | 2.20M | 2.04M | 1.15M | 632.00K |
| Cost of Revenue | 221.56M | 12.11M | 9.44M | 180.65M | 145.92M | 114.87M | 65.73M | 65.62M | 67.13M | 56.74M | 36.98M | 31.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.23M | -700.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -45.33M | 99.19M | 101.26M | -62.46M | -43.49M | -30.41M | -29.16M | -46.23M | -27.59M | -10.87M | -12.85M | -10.05M | 10.32M | 20.81M | 22.19M | 16.19M | 9.10M | 7.89M | 2.48M | 1.32M | 2.58M | 4.34M | 4.89M | 8.67M | 2.90M | 2.04M | 1.15M | 632.00K |
| Gross Profit Ratio | -25.72% | 89.12% | 91.47% | -52.84% | -42.46% | -36.01% | -79.75% | -238.43% | -69.78% | -23.71% | -53.23% | -46.43% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 252.40% | 131.82% | 100.00% | 100.00% | 100.00% |
| Research & Development | 234.06M | 249.90M | 230.82M | 180.65M | 145.92M | 114.87M | 65.73M | 65.62M | 67.20M | 56.74M | 36.98M | 31.71M | 32.10M | 33.15M | 28.98M | 31.23M | 25.56M | 21.53M | 11.42M | 11.05M | 10.19M | 13.36M | 15.51M | 11.35M | 4.30M | 4.26M | 1.70M | 628.00K |
| General & Administrative | 61.17M | 62.68M | 63.22M | 67.10M | 61.69M | 46.74M | 27.20M | 26.33M | 19.20M | 15.68M | 13.80M | 12.14M | 14.04M | 12.59M | 12.61M | 10.33M | 8.31M | 7.09M | 4.51M | 4.26M | 3.59M | 4.16M | 4.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 663.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.17M | 62.68M | 63.22M | 67.10M | 61.69M | 46.74M | 27.20M | 26.33M | 19.20M | 15.68M | 13.80M | 12.14M | 14.04M | 12.59M | 12.61M | 10.33M | 8.31M | 7.09M | 4.51M | 4.92M | 3.59M | 4.16M | 4.75M | 4.57M | 1.80M | 1.24M | 797.00K | 322.00K |
| Other Expenses | 155.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 887.00K | 431.00K | 364.00K | 82.00K | -66.00K | 14.04M | 0.00 | 0.00 | 10.33M | 8.31M | 7.09M | 4.81M | 4.92M | 4.16M | 22.17M | 13.06M | 9.80M | 2.50M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 450.24M | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M | 92.93M | 91.95M | 86.40M | 72.42M | 50.78M | 43.85M | 46.14M | 45.74M | 41.59M | 41.56M | 33.87M | 28.61M | 16.23M | 15.97M | 14.35M | 35.54M | 20.26M | 21.15M | 6.80M | 5.50M | 2.50M | 950.00K |
| Cost & Expenses | 450.24M | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M | 92.93M | 91.95M | 86.40M | 72.42M | 50.78M | 43.85M | 46.14M | 45.74M | 41.59M | 41.56M | 33.87M | 28.61M | 16.23M | 15.97M | 14.35M | 35.54M | 20.26M | 15.92M | 6.10M | 5.50M | 2.50M | 950.00K |
| Interest Income | 11.10M | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 71.00K | 81.00K | 0.00 | 2.23M | 3.22M | 2.41M | 850.00K | 620.00K | 752.00K | 1.37M | 3.19M | 3.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 139.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.19M | 12.11M | 9.44M | 5.68M | 3.93M | 2.36M | 1.50M | 997.00K | 988.00K | 549.00K | 569.00K | 660.00K | 646.00K | 676.00K | 572.00K | 523.00K | -1.87M | -686.00K | 488.00K | 1.48M | 2.17M | 2.51M | 4.31M | 5.23M | 700.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -87.43M | -189.17M | -173.90M | -123.87M | -101.25M | -74.79M | -54.86M | -70.68M | -45.80M | -26.23M | -26.08M | -21.54M | -35.10M | -24.18M | -18.83M | -24.85M | -24.77M | -20.73M | -13.26M | -13.38M | -9.60M | -27.89M | -11.07M | -7.25M | -3.20M | -3.46M | -1.35M | -318.00K |
| EBITDA Ratio | -49.61% | -180.85% | -165.61% | -109.61% | -102.69% | -91.35% | -154.13% | -374.23% | -118.51% | -57.38% | -110.16% | -102.51% | -347.14% | -119.85% | -86.08% | -146.39% | -273.08% | -268.65% | -505.80% | -1,017.64% | -372.82% | -247.18% | 40.80% | -211.21% | -145.45% | -169.68% | -116.75% | -50.32% |
| Operating Income | -274.01M | -201.28M | -183.34M | -129.55M | -105.18M | -77.15M | -56.36M | -72.56M | -46.86M | -26.78M | -26.71M | -22.20M | -35.82M | -24.94M | -19.40M | -25.38M | -24.77M | -20.73M | -13.75M | -14.65M | -11.77M | -31.57M | -28.44M | -12.48M | -3.90M | -3.46M | -1.35M | -318.00K |
| Operating Income Ratio | -155.48% | -180.85% | -165.61% | -109.61% | -102.69% | -91.35% | -154.13% | -374.23% | -118.51% | -58.38% | -110.66% | -102.51% | -347.14% | -119.85% | -87.45% | -156.77% | -272.27% | -262.89% | -553.46% | -1,114.07% | -456.34% | -726.80% | -582.21% | -363.62% | -177.27% | -169.68% | -116.75% | -50.32% |
| Total Other Income/Expenses | 11.10M | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M | 1.79M | 887.00K | 431.00K | 364.00K | 82.00K | -66.00K | 71.00K | 81.00K | 815.00K | 1.07M | 3.29M | 2.87M | 455.00K | 832.00K | 1.34M | 1.80M | 3.19M | 0.00 | 0.00 | 3.46M | 1.35M | 318.00K |
| Income Before Tax | -262.90M | -191.85M | -177.99M | -120.78M | -95.42M | -68.89M | -54.57M | -71.67M | -46.43M | -26.42M | -26.62M | -22.26M | -35.75M | -24.85M | -18.59M | -24.30M | -21.48M | -17.86M | -13.29M | -13.82M | -10.43M | -29.76M | -25.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -149.18% | -172.37% | -160.79% | -102.19% | -93.16% | -81.57% | -149.23% | -369.65% | -117.42% | -57.59% | -110.32% | -102.81% | -346.45% | -119.46% | -83.77% | -150.14% | -236.10% | -226.56% | -535.14% | -1,050.80% | -404.54% | -685.33% | -516.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.07M | 429.00K | 306.00K | 345.00K | -19.60M | 8.26M | -1.50M | -14.00K | -5.72M | -683.00K | -591.00K | -660.00K | -646.00K | -676.00K | -815.00K | -1.07M | -1.42M | -2.18M | -455.00K | -832.00K | -1.34M | -1.43M | 9.87M | -3.42M | -100.00K | 3.29M | 1.40M | 308.00K |
| Net Income | -257.83M | -192.28M | -178.30M | -121.12M | -75.82M | -68.33M | -54.57M | -71.66M | -40.70M | -26.42M | -26.62M | -22.26M | -35.75M | -24.85M | -18.59M | -24.30M | -21.48M | -17.86M | -13.29M | -13.82M | -10.43M | -29.76M | -25.25M | -9.07M | -3.80M | -3.29M | -1.40M | -308.00K |
| Net Income Ratio | -146.30% | -172.76% | -161.06% | -102.48% | -74.02% | -80.91% | -149.23% | -369.58% | -102.94% | -57.59% | -110.32% | -102.81% | -346.45% | -119.46% | -83.77% | -150.14% | -236.10% | -226.56% | -535.14% | -1,050.80% | -404.54% | -685.33% | -516.87% | -264.08% | -172.73% | -161.19% | -121.53% | -48.73% |
| EPS | -1.48 | -1.25 | -1.23 | -0.90 | -0.68 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 | -0.44 | -0.60 | -0.58 | -0.55 | -0.51 | -0.55 | -0.42 | -1.22 | -1.09 | -0.52 | -0.63 | -0.56 | -0.26 | -0.06 |
| EPS Diluted | -1.48 | -1.25 | -1.23 | -0.90 | -0.68 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 | -0.44 | -0.60 | -0.58 | -0.55 | -0.51 | -0.55 | -0.42 | -1.22 | -1.09 | -0.52 | -0.63 | -0.56 | -0.26 | -0.06 |
| Weighted Avg Shares Out | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | 42.05M | 40.83M | 37.36M | 32.50M | 25.86M | 25.13M | 24.81M | 24.49M | 23.12M | 17.38M | 6.01M | 5.84M | 5.49M | 5.14M |
| Weighted Avg Shares Out (Dil) | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | 42.05M | 40.83M | 37.36M | 32.50M | 25.86M | 25.13M | 24.81M | 24.49M | 23.12M | 17.38M | 6.01M | 5.84M | 5.49M | 5.14M |
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check.
3 Penny Stocks To Buy With Just $750
Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports